Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VK2735 Drug · 1 trial · 1 indication
-Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo Subcutaneously (SC) weekly |
| VK2735 Dose Level 2 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly |
| VK2735 Dose Level 3 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously weekly |
| VK2735 Dose Level 4 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week |
| VK2735 Dose Level 5 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly |
| VK2735 Dose Level 6 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly |
| VK2735 Dose Level 7 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly |
| VK2735 Dose Level 8 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly |
| VK2735 Dose Level 9 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly |
| VK2735 Dose Level 10 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week |
| VK2735 Dose Level 11 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week |
| VK2735 Dose Level 12 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly |
| VK2735 Dose Level 14 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 orally once daily |
| VK2735 Dose Level 15 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 orally once daily |
| VK2735 Dose Level 16 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 orally once daily |
| VK2735 Dose Level 17 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by Placebo orally once weekly |
| VK2735 Dose Level 18 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by Placebo orally once daily |
| VK2735 Dose Level 13 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 orally weekly |
| Name | Type | Description |
|---|---|---|
| VK2735 Drug | DRUG | SC or oral once daily, once weekly, every other week, or monthly |
| Placebo | DRUG | SC or oral once daily or once weekly |
Inclusion Criteria: * Must be capable of giving a signed informed consent form (ICF). * Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opi...